Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Public ClinicalTrials.gov record NCT03776812. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.
Study identification
- NCT ID
- NCT03776812
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 178 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 5, 2019 (Actual)
- Primary completion
- Mar 16, 2021 (Actual)
- Completion
- Jul 12, 2023 (Actual)
- Last update posted
- Oct 7, 2025
2019 – 2023
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator #004 | Birmingham | Alabama | 35249 | — |
| Site Reference ID/Investigator #038 | Scottsdale | Arizona | 85258 | — |
| Site Reference ID/Investigator #032 | Denver | Colorado | 80045 | — |
| Site Reference ID/Investigator #001 | Chicago | Illinois | 60637 | — |
| Site Reference ID/Investigator #106 | Boston | Massachusetts | 02215 | — |
| Site Reference ID/Investigator #128 | Boston | Massachusetts | 02215 | — |
| Site Reference ID/Investigator #051 | New York | New York | 10065 | — |
| Site Reference ID/Investigator #169 | New York | New York | 10065 | — |
| Site Reference ID/Investigator #170 | New York | New York | 10065 | — |
| Site Reference ID/Investigator #127 | Pittsburgh | Pennsylvania | 15213 | — |
| Site Reference ID/Investigator #135 | Charlottesville | Virginia | 22908 | — |
| Site Reference ID/Investigator #121 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03776812, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 7, 2025 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03776812 live on ClinicalTrials.gov.